Clotrimazole
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Clotrimazole: From Fungal Infections to Acne (Disease)
One-Sentence Summary
Clotrimazole is a topical imidazole antifungal, established for treating dermatophyte and candidal infections (e.g. tinea, vulvovaginal candidiasis). The TxGNN model’s top-ranked prediction in this evidence pack is Acne (disease), but this is currently supported by only 1 clinical trial (suspended, fixed-dose combination product) and no dedicated literature.
Note: This evidence pack contains 10 ranked predictions for clotrimazole. The one below (rank 1, highest TxGNN score) is reported per the standard extraction rule, but it is not the best-evidenced candidate in the pack — rank 2 (“vulvovaginitis”) has L1 evidence (multiple completed Phase 3/4 RCTs) and a “Proceed with Guardrails” recommendation, though that largely reflects clotrimazole’s already-established use rather than a novel repurposing signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established in this evidence pack — no UK marketing authorisation is on record for Clotrimazole |
| Predicted New Indication | Acne (disease) |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Clotrimazole in this evidence pack (flagged as a High-severity data gap). Based on known pharmacological class information referenced elsewhere in the evidence pack, Clotrimazole is a broad-spectrum imidazole antifungal that inhibits fungal CYP51 (14α-demethylase), disrupting ergosterol synthesis in the fungal cell membrane; its efficacy in dermatophyte and candidal infections is well established.
Acne, however, is primarily a disorder of sebaceous gland activity, follicular hyperkeratinisation, and Cutibacterium acnes-driven inflammation — it is not a fungal disease. The mechanistic link is therefore indirect: it applies mainly to “fungal acne” (Malassezia folliculitis), a yeast-driven condition frequently misdiagnosed clinically as acne, rather than to acne vulgaris itself.
The single relevant trial identified is a fixed-dose triple combination (beclometasone + gentamicin + clotrimazole), from which clotrimazole’s individual contribution cannot be isolated, and the trial was suspended before completion. Taken together, the mechanistic rationale is plausible only in a specific misdiagnosed subgroup, and the clinical evidence base is insufficient to support this prediction at present.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT01244256 | Phase 2/3 | Suspended | 80 | Evaluated a combination cream (beclometasone 0.025% + gentamicin 0.1% + clotrimazole 1%) in patients with contaminated dermatosis showing bilateral symmetrical lesions; trial suspended, and effect cannot be attributed to clotrimazole alone |
Literature Evidence
Currently no related literature available.
UK Market Information
No UK marketing authorisations are on record for Clotrimazole in this evidence pack (market status: Not marketed; total licences: 0).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: this evidence pack flags a Blocking-severity data gap for TFDA/MHRA label warnings and contraindications, and a High-severity gap for mechanism-of-action data — both must be resolved before any formal safety assessment (S1) can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic link between clotrimazole’s antifungal activity and acne pathology is indirect and applies mainly to a misdiagnosed subgroup (fungal acne), and the only supporting trial is a suspended combination-product study from which clotrimazole’s individual effect cannot be isolated. Evidence level (L4) is insufficient to support progression.
To proceed, the following is needed:
- Mechanism of action (MOA) data for Clotrimazole (currently a data gap)
- UK/MHRA label warnings and contraindications (currently a data gap; Blocking severity)
- Dedicated clinical evidence in a confirmed fungal-acne (Malassezia folliculitis) population, distinct from acne vulgaris
- Clarification of UK regulatory/marketing status, since no licences are currently on record
- If pursuing further, consider whether rank-2 candidate (vulvovaginitis, L1 evidence) better reflects an actionable, evidence-supported use case
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.